Acute and subacute macular and peripapillary angiographic changes in choroidal and retinal blood flow post-intravitreal injections

Arumuganathan, Nadhini; Wiest, Maximilian Robert Justus; Toro, Mario Damiano; Hamann, Timothy; Fasler, Katrin; Zweifel, Sandrine

doi:10.1038/s41598-021-98850-8

Cited by 10 publications

(13 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There have been reports on the assessment of corneal thickness (CT) (Muscat et al, 2002;Ishibazawa et al, 2011); AS-OCT also contributes to the diagnosis of anterior eye diseases, monitoring of pathological conditions, and their healing process (Nubile et al, 2011;Mastropasqua et al, 2017;Venkateswaran et al, 2018;Kowalczyk et al, 2020). OCT technology is also widely used for posterior segment imaging; several studies have shown its effectiveness in disease monitoring with good intrasession reproducibility even in case of corneal pathologies (Reibaldi et al, 2012), as well as in detecting the onset of possible treatment-related complications (Ceravolo et al, 2020;Arumuganathan et al, 2021). Furthermore, it is commonly used as a screening tool for not only ocular diseases but also systemic diseases (Chisari et al, 2019;Carnevali et al, 2021;Koman-Wierdak et al, 2021;Wiest et al, 2021;Zweifel et al, 2021).…”

Section: Introductionmentioning

confidence: 99%

Recombinant Human Nerve Growth Factor (Cenegermin)–Driven Corneal Wound Healing Process: An Evidence-Based Analysis

et al. 2022

View full text Add to dashboard Cite

Purpose: To evaluate anterior segment optical coherence tomography (AS-OCT) to detect the wound healing process as per monitoring the effectiveness of cenegermin to treat moderate to severe neurotrophic keratoplasty.Methods: A retrospective chart review was realized to identify patients treated with cenegermin at the Clinica Oculistica, University of Genoa, Italy. All patients underwent careful examinations at baseline and follow-up visits. AS-OCT scans centered on the minimum corneal thickness (CT) area were always performed. We compared findings of AS-OCT with the findings from the slit-lamp examination. A linear regression analysis was used to evaluate factors associated with corneal healing. A further analysis, including a control group treated with 50% autologous serum (AS), was done to investigate and compare the efficacy of cenegermin.Results: Data from 16 eyes were studied. The average patients' age was 60.9 ± 21.1 years; five (31.2%) eyes experienced persistent epithelial defect and 11 (68.8%) eyes had neurotrophic corneal ulcer. The average reepithelialization time was 3.9 ± 0.5 weeks in the cenegermin group versus 5.9 ± 1.9 weeks in the AS group (p < 0.01). The AS‐OCT scans revealed an average CT at the thinnest point of 276.3 ± 74.1 μm before treatment with an average increase of 176.5 ± 60.3 μm at the end of the cenegermin treatment (B = −0.15; p = 0.035). The AS-OCT percentage increase in corneal thickness between the two groups was statistically significant (p < 0.02).Conclusion: Understanding the cascade of events involved in the nerve growth factor–driven corneal wound healing process is clinically meaningful for the clinician. AS-OCT is an effective tool for systematic anterior segment imaging, allowing the detailed detection of the front-to-back layered corneal structure for quantitative analysis and monitoring of the healing process.

show abstract

Section: Introductionmentioning

confidence: 99%

Recombinant Human Nerve Growth Factor (Cenegermin)–Driven Corneal Wound Healing Process: An Evidence-Based Analysis

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Despite surgery, persistent or recurrent DME can occur, and it is difficult to treat due to the increased clearance of medications in the vitreous cavity of vitrectomized eyes ( Gunay and Erdogan, 2021 ). Previous studies ( Yanyali et al, 2007 ; Pessoa et al, 2018 ; Pessoa et al, 2019 ; Arumuganathan et al, 2021 ) observed the persistence of DME up to 22% of eyes with TDME treated with PPV.…”

Section: Introductionmentioning

confidence: 82%

“…To date, intravitreal therapy (IVT) with anti-vascular endothelial growth factor (VEGF) agents or steroids is considered a first-line treatment of DME ( Bucolo et al, 2018 ; Kodjikian et al, 2019 ; Arumuganathan et al, 2021 ; Elfalah et al, 2021 ). However, the treatment of tractional DME (TDME) with IVT of anti-VEGF or corticosteroids may be poorly effective due to a possible influence of tractional forces ( Sadiq et al, 2016 ; Chang et al, 2017 ).…”

Section: Introductionmentioning

confidence: 99%

Efficacy and Safety of Subthreshold Micropulse Yellow Laser for Persistent Diabetic Macular Edema After Vitrectomy: A Pilot Study

et al. 2022

Self Cite

View full text Add to dashboard Cite

Aim: To examine the effect of subthreshold micropulse yellow laser (SMYL) on best-corrected visual acuity (BCVA), central macular thickness (CMT), and optical coherence tomography angiography (OCT-A) changes in eyes with persistent diabetic macular edema (DME) after pars plana vitrectomy (PPV) for tractional DME (TDME).Patients and Methods: In a comparative study, 95 eyes of 95 consecutive patients with persistent DME were prospectively enrolled. The SMYL group (54 eyes) was treated with SMYL 6 months after PPV, while the control group (41 eyes) was followed up without treatment. BCVA and CMT by OCT were analyzed at baseline and 3 and 6 months. Additionally, parameters such as the vessel density (VD) in the superficial capillary plexus (SCP) and deep capillary plexus (DCP), respectively, and the area of the foveal avascular zone (FAZ) were also evaluated on OCT-A.Results: There were no significant differences between both groups in demographic data. In the SMYL group, mean BCVA was significantly increased [F(2,106) = 17.25; p < 0.001; ηp2 = 0.246] from 51.54 ± 13.81 ETDRS letters at baseline to 57.81 ± 12.82 ETDRS letters at 3 months (p < 0.001) and 57.83 ± 13.95 EDTRS letters at 6 months (p < 0.001), respectively. In comparison to the control group, BCVA values were statistically significantly higher in the SMYL group at 3 and 6 months, respectively. Mean CMT significantly decreased [F(2,106) = 30.98; p < 0.001; ηp2 = 0.368] from the baseline value 410.59 ± 129.91 μm to 323.50 ± 89.66 μm at 3 months (p < 0.001) and to 283.39 ± 73.45 μm at 6 months (p < 0.001). CMT values were significantly lower in the SMYL group (p < 0.001), especially at 6 months follow-up time (p < 0.001) compared with the control group. Parafoveal VD in the SCP and DCP was significantly higher in the SMYL group in comparison to the control group, respectively, at 3-month (SCP p < 0.001; DCP p < 0.001) and 6-month follow-up (SCP p < 0.001; DCP p < 0.001). FAZ area was also significantly smaller in the SMYL group at 6-month follow-up (p = 0.001). There were no adverse SMYL treatment effects.Conclusion: SMYL therapy may be a safe and effective treatment option in eyes with persistent macular edema following PPV for TDME.

show abstract

“…Enjeksiyon öncesi ve enjeksiyondan sonra erken dönemde (5.dk ve 1.gün) FAZ ve damar yoğunluğu değerlerinde anlamlı farklılık izlenmemiştir. 10…”

Section: Introductionunclassified

Short Term Effects of Anti-VEGF Agents on Retinal Vascularity

Bayrakceken

2023

Gümüşhane Üniversitesi Sağlık Bilimleri Dergisi

View full text Add to dashboard Cite

Bu çalışmada, retinal vasküler hastalıklara ve yaşa bağlı makula dejenerasyonuna ikincil gelişen maküla ödeminin tedavisi için anti-vasküler endotelyal büyüme faktörü (VEGF) enjeksiyonu uygulanan hastalarda akut dönemde optik koherens tomografi (OCT) ve optik koherens tomografi anjiyografi (OCTA) görüntülemeleri kullanılarak makülada ve retinal vasküler yapılardaki erken dönem değişikliklerin değerlendirilmesi amaçlanmıştır. Retrospektif çalışmamız için Erzincan Binali Yıldırım Üniversitesi Göz Hastalıkları Kliniği’nde Kasım 2021 ile Kasım 2022 tarihleri arasında kliniğimizde retinal vasküler hastalık nedeniyle takip edilen, tedavilerinde anti-VEGF uyguladığımız, enjeksiyon öncesi ve sonrası erken dönemde OCT ve OCTA görüntülemeleri yapılan 30 hastanın 30 gözü dahil edilmiştir. Enjeksiyon öncesi ve sonrası (10.dakika,1.gün ve 1.hafta) OCT ve OCTA bulgularında foveal avasküler zon dışında anlamlı değişiklik saptanmıştır (p˂0,05). Retinal vaküler hastalıklara bağlı maküler ödem tedavisinde uyguladığımız anti-VEGF tedavisi sonrası akut dönemde maküla kalınlığında ve damar yoğunluğunda azalma olduğu görülmüştür. Daha geniş katılımlı çalışmalara ihtiyaç vardır.

show abstract

Acute and subacute macular and peripapillary angiographic changes in choroidal and retinal blood flow post-intravitreal injections

Cited by 10 publications

References 48 publications

Recombinant Human Nerve Growth Factor (Cenegermin)–Driven Corneal Wound Healing Process: An Evidence-Based Analysis

Recombinant Human Nerve Growth Factor (Cenegermin)–Driven Corneal Wound Healing Process: An Evidence-Based Analysis

Efficacy and Safety of Subthreshold Micropulse Yellow Laser for Persistent Diabetic Macular Edema After Vitrectomy: A Pilot Study

Short Term Effects of Anti-VEGF Agents on Retinal Vascularity

Contact Info

Product

Resources

About